Analysis of Pfizer's best selling drugs in 2016

When it comes to Pfizer, we are all familiar Pfizer is the No 1 pharmaceutical company in the world, starting with santaonian, terramycin and penicillin, and now has nearly 100000 employees in 150 countries and regions In addition to the R & D strength, what the outside world is more interested in is its strong marketing team, through the "marketing + M & a" business strategy to establish its position as the first brother in the pharmaceutical industry In 2016, Pfizer achieved a total revenue of 52.824 billion US dollars, an increase of 8.13% compared with 2015, of which patent drugs contributed 29.197 billion US dollars, accounting for 55.27%; traditional drugs achieved a revenue of 23.627 billion US dollars, accounting for 44.73% In the field of innovative drugs, internal medicine, vaccines, and tumors rank the top three in sales revenue, and the specific proportion is shown in the following figure: for a single variety, vaccine product prevent13, painkiller Lyrica, tumor necrosis factor α inhibitor Enbrel, anti-tumor drug ibrance, lipid-lowering drug Lipitor rank the top five, and the total sales volume of a single variety ranks the top 10, as shown in the table below: In 2016, Pfizer's top 10 best-selling drugs achieved a total revenue of US $23.051 billion, accounting for 43.6% of Pfizer's total drug sales in 2016, including four non patented drugs (Lipitor, Viagra, premarin and Norvasc) that have been sold for many years, including two vaccine and biological preparation varieties (preventer and Enbrel), two anti-tumor and rheumatoid arthritis varieties in the top 10, and 20 preventer 15 years later, Pfizer became the best seller 10 xeljanz xeljanz (tofacitinib / tofacitinib), a novel oral Janus kinase (JAK) inhibitor, affects DNA transcription by interfering with JAK-STAT signaling pathway, reduces cytokine signaling, cytokine induced gene expression and cell activation Xeljanz was approved by the FDA in 2012 and CFDA in 2017 for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who were not adequately or tolerably relieved by methotrexate (MTX) In addition, xeljanz has also achieved good clinical results in the field of psoriasis and ulcerative colitis Xeljanz is one of the fastest growing products in Pfizer's sales performance Since 2013, the annual sales growth of xeljanz has reached 170%, 69.8% and 77.2% respectively, which has become a new driving force for Pfizer's performance growth Tophatinib's compound patent and crystal patent will expire in 2020 and 2022 respectively At present, in addition to the original research, 40 domestic enterprises have applied for the variety, which is quite competitive Norvasc Norvasc (huoluoxi / amlodipine), since its inception in 1990, is one of the world's largest prescription brand drugs for the treatment of hypertension Indications: hypertension, can be used alone or in combination with other antihypertensive drugs For adult patients with hypertension, generally speaking, lowering blood pressure can reduce the risk of cardiovascular events, mainly stroke and myocardial infarction; coronary heart disease (CAD): including chronic stable angina; vasospasm angina (prinzme tal's or variant angina), which is confirmed by angiography In the face of generic competition, Norvasc's market share has gradually declined, and its sales volume has fallen below $1 billion since 2015 In the domestic amlodipine market, the top five enterprises are Pfizer pharmaceutical 85.6%, Cr SECCO 4.97%, Yangzijiang Pharmaceutical Group Shanghai haini pharmaceutical 3.34%, Jiangsu Suzhou Dongrui pharmaceutical 2.27%, Yunnan Kunming Sinopharm 1.37% Premarin (CO njugated Estrogens/ premep / conjugated estrogen), a postmenopausal hormone replacement therapy, includes moderate and severe vasomotor dysfunction associated with estrogen deficiency, prevention and treatment of osteoporosis, reduction of the incidence rate of coronary heart disease and related mortality in postmenopausal women, treatment of atrophic vaginitis and atrophic urethritis, and hypo estrogen in women In recent years, premarin series products have maintained a stable sales performance of about $1 billion 7 Sutent SUTENT (sunitinib / sunitinib / sotan) is a small molecule tyrosine kinase inhibitor, which inhibits platelet-derived growth factor receptor (PDGFR α and PDGFR β), vascular endothelial growth factor receptor (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (Kit), FMS like tyrosine kinase-3 (FLT3), colony stimulating factor receptor (CSF-1R) and neuroglial cell line derived nerve Many targets, such as RET, have antitumor and antiangiogenic effects In 2006, imatinib mesylate was approved by FDA and European Union In 2007, imatinib mesylate was introduced into China The indications were failure or intolerable gastrointestinal stromal tumor, inoperable advanced renal cell carcinoma and unresectable, metastatic advanced pancreatic neuroendocrine tumor As a second-line drug for renal cancer and gastrointestinal stromal tumor, SUTENT's sales performance has not fluctuated much in recent years Its patent will expire in 2021 There are 9 domestic enterprises applying for this product, including Zhengda Tianqing, Shiyao, Hengrui, Qilu, etc 6 Viagra's mysterious little blue pill - Viagra has a good therapeutic effect on pulmonary hypertension, a rare disease, in addition to the well-known erectile dysfunction (20 mg for pulmonary hypertension, three times a day; 100 mg for penile erectile dysfunction, one hour before it needs to be taken) In recent years, Viagra's sales performance has remained stable at about $1.7 billion In the domestic market, in addition to the listing of Baiyunshan's Jinge, 41 enterprises have applied for the product Meanwhile, innovative drug research on PDE-5 inhibitors is also underway in China: tpn729 of Shanghai Pharmaceutical Institute is a highly selective PDE-5 inhibitor, which has the characteristics of high activity, good selectivity, clear efficacy, low toxicity, excellent pharmacokinetic properties, etc., which can reduce the current clinical effect There are some adverse reactions of PDE5 inhibitor; Xiong dinafei et al 5 Lipitor, once the world's best-selling drug, saw a precipitous decline in Lipitor's sales after the generic drug was launched in 2012 The decline trend has eased after 14 years, and it still brings good benefits to Pfizer every year It is expected that Lipitor's sales in 2017 will remain at about $1.7 billion 4 ibrance ibrance (palbociclib / pabosini), palbociclib is the world's first listed cyclin dependent kinase (CDK4 / 6) inhibitor, which was approved by FDA in February 2015 and listed in the EU in November 2016 FDA is based on the results of a randomized, open, multicenter phase II clinical trial (paloma-1) to accelerate the approval of ibrance In the paloma-1 trial, ibrance combined with letrozole was used as the basic regimen of endocrine therapy for 165 patients with postmenopausal ER + / HER2 - advanced breast cancer The main end point of the study was reached The PFS of the treatment group with ibrance and letrozole was significantly higher than that of the control group (20.2 months vs 10.2 months) The confirmatory clinical trial of ibrance is a randomized, double-blind, multicenter phase III clinical trial (paloma-3) Patients with advanced metastatic breast cancer, whether postmenopausal or postmenopausal, were treated with ibrance and fluvastatin Paloma-3 was terminated because it reached the main end point ahead of time The median PFS of Irvine group was 4.9 months longer than that of the single group Based on this result, the FDA expanded the approval of ibrance for the treatment of HR + / HER2 - advanced metastatic breast cancer patients At present, the United States is the main market of ibrance, accounting for 96.8% of its total sales in 2016 According to Pfizer's quarterly report in 2016, the sales of ibrance outside the U.S market are 0.7 billion, 0.12 billion, 0.19 billion and 0.3 billion (US dollars), respectively In view of the fact that ibrance was approved by the European Union at the end of 2016, the overseas sales of ibrance increased by 58% in the fourth quarter We have reason to look forward to it Performance in 2017 In addition to trastuzumab, in March 2017, ribociclib of Novartis, in combination with aromatase inhibitors, was used as the initial endocrine treatment program for postmenopausal women with hormone receptor positive and human epidermal growth factor receptor-2 negative (HR + / HER2 -) who had advanced or metastatic breast cancer In 2017, breast cancer was approved It remains to be seen who will win the cancer treatment market In the domestic market, in addition to Pfizer, 19 enterprises of this product are in the application stage 3 Enbrel Enbrel (enri / etanercept / etanercept), a fusion protein tumor necrosis factor α inhibitor for the treatment of rheumatoid arthritis and ankylosing spondylitis jointly developed by Pfizer and Amgen, is a dimer fusion protein, which is composed of the extracellular ligand binding part of human 75kd tumor necrosis factor receptor and human igg1fc segment The FC segment contains GH2 region and CH3 region hinge region, but not ch1 region It can specifically bind to TNF α receptor, block the interaction between TNF and TNF α receptor on cell surface, and regulate the biological function of TNF α induction or mediation At present, the approved indications of Enbrel include: moderate to severe rheumatoid arthritis, moderate to severe polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and moderate to severe plaque psoriasis over 4 years old The drug generated $2.9 billion in revenue for Pfizer in North America (excluding Canada) in 2016 The bioequivalent drugs of the drug include etanercept SZZS of Novartis, benepali developed by Samsung bioepis, qiangke of SAIJIN bio, a domestic manufacturer, yisaipu of Sansheng Guojian, etc 2 Lyrica Lyrica (lerica / pregabalin), a GABA receptor antagonist, has been rated as "one of the top ten medical advances in 2007" by time At present, the drug has been listed in dozens of countries and regions, and it is a veritable heavy bomb drug In 2016, the global sales volume of pregabalin was 4.966 billion US dollars, up 2.6% from 2015 Pregabalin binds to the voltage-gated calcium channel assistant subunit (α 2-δ protein) in the central nervous system, which has antiepileptic, analgesic and anti anxiety effects FDA and EU approved Pfizer's pregabalin capsule in 2004 At present, the indications approved by FDA and EU are neuralgia related to diabetic peripheral neuropathy, postherpetic neuralgia and adjuvant treatment of adult partial epilepsy In addition, the European Union approved in March 2006 for the treatment of generalized anxiety disorder, in September 2006 for the treatment of adult central neuralgia (including spinal cord injury, stroke and neuralgia accompanied by multiple sclerosis); in 2007, it was approved in the United States for the treatment of fibromyalgia Pregabalin's compound patent and pain application patent will expire in 2018 The generic drug market has a huge prospect, and the domestic competition for this product is very fierce At present, there are sales of Pfizer and pregabalin capsule produced by Chongqing Saiwei Pharmaceutical Co., Ltd in the domestic market 1 preventer preventer, including preventar7 and preventar13, is the most widely used pneumococcal conjugate vaccine (PCV) in the world and the best-selling vaccine in the world, with global sales of 5.7 billion US dollars in 2016 Prevnar 13 is an important product of Pfizer vaccine industry pipeline, which is a 13 valent Streptococcus pneumoniae combined vaccine, initially developed by Wyeth Pfizer spent $68 billion in 2009 to pocket the prevent13 Prevnar approved by FDA in 2010